白塞病神经眼科表现的特征与转归
该回顾性单中心研究纳入217例神经白塞病患者,其中29例(13.3%)出现神经眼科表现,分为实质型13例与非实质型16例;所有患者接受糖皮质激素治疗,79%加用免疫抑制剂,治疗后66.7%视力改善或稳定,33.3%恶化。
要点
- 神经眼科表现占神经白塞病的13.3%,45%为首发表现。
- 非实质型均表现为脑静脉血栓相关视乳头水肿,实质型以视乳头炎为主。
- 治疗后66.7%视力改善或稳定,33.3%恶化;法定盲从10.3%降至3.4%。
核心结论
- 神经眼科表现占神经白塞病的13%,可能严重致残,及时治疗是改善视力转归的关键因素。
研究设计与样本
- 回顾性单中心研究,纳入217例确诊神经白塞病患者,其中29例(13.3%)出现神经眼科表现。
主要发现
- 29例中男性占55%,平均年龄26±8岁;45%以神经眼科表现为白塞病首发,55%在病程中出现。
- 实质型13例(45%),包括视乳头炎7例(53.8%)、球后视神经炎4例(30.8%)、第三脑神经麻痹2例(15.4%)。
- 非实质型16例(55%),均表现为脑静脉血栓相关视乳头水肿,其中6例(37.5%)伴第六脑神经麻痹。
- 初诊时93.1%患者有视觉异常,主要为视力下降、视野缺损和/或复视。
- 治疗后66.7%视力改善或稳定,33.3%恶化;最小分辨角对数视力从诊断时0.4±0.3改善至治疗后0.2±0.3。
临床怎么用
- 所有患者接受糖皮质激素治疗,79%接受免疫抑制剂治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The neuro-ophthalmological manifestations of Behcet's disease (BD) are rare, and data regarding their characteristics and outcome are lacking. OBJECTIVE: To report prevalence, main characteristics and outcome of neuro-ophthalmological manifestations in BD. PATIENTS AND METHODS: This is a retrospective monocentric study of 217 patients diagnosed with neuro-Behçet's disease (NBD), of whom 29 (13.3%) patients presented with neuro-ophthalmological manifestations (55% of men and mean±SD age of 26±8 years). All patients underwent a detailed ophthalmological examination and were followed up in the internal medicine and the ophthalmology departments. RESULTS: Neuro-ophthalmological manifestations were the first presentation of BD in 45% of patients and developed later in the course of the disease in 55% of patients. They are divided into parenchymal (PM) and non-parenchymal (NPM)-related manifestations in, respectively, 13 patients (45%) and 16 patients (55%). PM included papillitis in seven patients (53.8%), retrobulbar optic neuritis in four patients (30.8%) and third cranial nerve palsy in two patients (15.4%). NPM included papilloedema related to cerebral venous thrombosis in all 16 patients, of whom 6 patients (37.5%) had sixth cranial nerve palsy. At initial examination, 93.1% of patients had visual alterations, including mainly decreased visual acuity visual field defects and/or diplopia. All patients were treated with corticosteroids and 79% of patients received immunosuppressive agents. After treatment, the visual outcome improved or stabilised in 66.7% of patients while it worsened in 33.3. The mean±SD logarithm of the minimum angle of resolution visual acuity improved from 0.4±0.3 at diagnosis to 0.2±0.3 after therapy. 10.3% and 3.4% of patients were legally blind at diagnosis and after therapy, respectively. CONCLUSION: Neuro-ophthalmological manifestations of BD represented 13% of NBD. They could be potentially severe and disabling. Prompt treatment is the key factor in improving visual outcome.
引用
- Alghamdi A, Bodaghi B, Comarmond C, et al. Neuro-ophthalmological manifestations of Behçet's disease. Br J Ophthalmol. 2018. PMID: 29699980. doi:10.1136/bjophthalmol-2017-311334
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。